T2S Group Invests 60 Million Dirhams in a Radiopharmaceuticals Manufacturing Plant in Fès
T2S Group Expands Investments in Nuclear Medicine in Morocco with New Radiopharmaceutical Production Facility in Fes
T2S Group is reinforcing its investments in the field of nuclear medicine in Morocco by constructing a new radiopharmaceutical production facility in Fes. This initiative, spearheaded by its subsidiary Cyclopharma, involves a total investment of 60 million Moroccan dirhams (approximately $6.1 million).
Construction work commenced on October 1, 2026. This new facility will serve as Cyclopharma’s second production site, following its location in Bouskoura-Oulad Saleh, near Casablanca. The facility is expected to be operational by the second quarter of 2028, depending on the progress of construction and the acquisition of the necessary regulatory approvals.
The project aims to enhance the national capacity for producing radiopharmaceuticals and improve the supply to healthcare establishments, particularly in the Fes-Meknes and Oriental regions.
These medications, utilized in nuclear medicine for diagnosing and monitoring several conditions, especially in oncology, cardiology, and neurology, require special manufacturing, safety, and transportation conditions. Some of them have very short radioactive lifespans, making the proximity of production units to healthcare facilities particularly crucial.
From a technical standpoint, the future site in Fes will feature a building with two levels of underground facilities, a ground floor, and three additional floors. It will house a bunker specifically designed to accommodate a cyclotron—an essential piece of equipment for producing radioisotopes—as well as manufacturing laboratories and areas dedicated to quality and radiological control.
The unit will also include secure storage spaces, equipment for managing radioactive waste, technical rooms, and administrative offices, all in compliance with the regulatory and radioprotection requirements relevant to this activity.
This investment is part of T2S Group Holding’s development program, which was presented during its initial public offering on the Casablanca Stock Exchange in July 2026. The program includes plans to expand radiopharmaceutical production capacity and develop an industrial model based on multiple sites throughout Morocco.
Through this new facility, the group aims to strengthen its presence in the field of nuclear medicine and contribute to enhancing the national supply of radiopharmaceuticals.
